全文获取类型
收费全文 | 2152篇 |
免费 | 102篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 85篇 |
妇产科学 | 37篇 |
基础医学 | 185篇 |
口腔科学 | 34篇 |
临床医学 | 205篇 |
内科学 | 487篇 |
皮肤病学 | 84篇 |
神经病学 | 251篇 |
特种医学 | 338篇 |
外科学 | 228篇 |
综合类 | 26篇 |
预防医学 | 93篇 |
眼科学 | 9篇 |
药学 | 122篇 |
中国医学 | 2篇 |
肿瘤学 | 123篇 |
出版年
2023年 | 14篇 |
2022年 | 21篇 |
2021年 | 35篇 |
2020年 | 25篇 |
2019年 | 29篇 |
2018年 | 46篇 |
2017年 | 19篇 |
2016年 | 28篇 |
2015年 | 29篇 |
2014年 | 47篇 |
2013年 | 75篇 |
2012年 | 69篇 |
2011年 | 63篇 |
2010年 | 60篇 |
2009年 | 89篇 |
2008年 | 65篇 |
2007年 | 95篇 |
2006年 | 77篇 |
2005年 | 58篇 |
2004年 | 56篇 |
2003年 | 52篇 |
2002年 | 43篇 |
2001年 | 43篇 |
2000年 | 47篇 |
1999年 | 66篇 |
1998年 | 81篇 |
1997年 | 93篇 |
1996年 | 110篇 |
1995年 | 72篇 |
1994年 | 63篇 |
1993年 | 64篇 |
1992年 | 45篇 |
1991年 | 40篇 |
1990年 | 43篇 |
1989年 | 50篇 |
1988年 | 47篇 |
1987年 | 57篇 |
1986年 | 58篇 |
1985年 | 50篇 |
1984年 | 23篇 |
1983年 | 18篇 |
1982年 | 20篇 |
1981年 | 13篇 |
1980年 | 15篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 14篇 |
1976年 | 13篇 |
1975年 | 15篇 |
1967年 | 6篇 |
排序方式: 共有2315条查询结果,搜索用时 15 毫秒
991.
A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation 总被引:18,自引:4,他引:14
A1, a bcl-2 family member, has been identified as a hematopoietic- specific, early inducible gene. In this study it is shown that stable transfection of A1 into an interleukin-3 (IL-3)-dependent myeloid precursor cell line, 32D c13, leads to a retardation of IL-3 withdrawal- induced cell death similar to that observed with transfection of bcl-2. However, unlike bcl-2. A1 expression permits the accumulation of differentiated myeloid cells both before and after IL-3 withdrawal. Total cell accumulation, on the other hand, is considerably greater after IL-3 deprivation in the bcl-2 transfectant than in A1-expressing cells. Cells cotransfected with the two genes behave similarly to cells singly transfected with bcl-2, except that viability following IL-3 withdrawal is somewhat further enhanced. These results suggest that these two proteins have distinct roles that may be related to the divergent regulation of their expression during myeloid differentiation. 相似文献
992.
993.
994.
995.
L. Bettoni M. Bazzani E. Bortone I. Dascola E. Pisani D. Mancia 《Acta neurologica Scandinavica》1994,90(4):276-280
A clinical and epidemiological study on amyotrophic lateral sclerosis (ALS) was conducted in the province of Parma, Italy, from 1960–1990. A total of 121 cases were collected from hospital records. The average annual incidence was 0.98 per 100000 inhabitants, with a male/female ratio of 1.1. Age-specific incidence was maximal in the age group 60–69 years. No difference between rural and urban areas was found. Prevalence on October 26th, 1981 was 2.5 per 100000. Mean age at onset was 60 years, with no significant sex difference. Mean duration of the disease was 30 (sd 21.4) months. Bulbar forms were significantly (p<0.05) shorter than conventional forms, with a mean duration of 23.4 (sd 21.4) months. Age at onset did not influence prognosis. A comparison of three decades was made, to verify whether possible variations of the disease had occurred with time. From our data a definite stability was found in such epidemiological parameters as incidence, prevalence, mean duration and mortality of ALS in the period. 相似文献
996.
997.
Groupe Coopératif Francophone J. C. Raphael S. Chevret Cl. Chastang Ph. Hantson Ph. Gautier O. Vandenplas M. Van Lierde G. Dooms J. -M. Guerit A. Keyeux P. Mahieu D. Annane G. Troché F. Delisle P. Devauchelle JC. Raphaël Ph. Gajdos F. Bouvet M. A. Quera Salva C. McCann C. Fromageot J. De Lattre J. Kempf J. M. Saissy Ph. Sauder 《Intensive care medicine》1992,18(2):S60-S61
998.
Kalinin is abnormally expressed in epithelial basement membranes of Herlitz''s junctional epidermolysis bullosa patients 总被引:6,自引:0,他引:6
G. Meneguzzi M. P. Marinkovich D. Aberdam A. Pisani R. Burgeson J. P. Ortonne 《Experimental dermatology》1992,1(5):221-229
Kalinin is an extracellular adhesion molecule specific to epithelial basement membranes (BM) identified as a component of anchoring filaments of hemidesmosomes. This heterotrimeric protein is synthesized by cultured normal human keratinocytes and is involved in cell attachment. In indirect immunofluorescence studies, the epidermal BM of patients with junctional epidermolysis bullosa (JEB) of Herlitz's type were found not to be reactive with the anti-kalinin monoclonal antibodies ka146 and K140 and displayed a decreased immunoreactivity to two anti-kalinin antibodies cross-reacting with K-laminin, an anchoring filament component recently described. The intrinsic defect of JEB keratinocytes in the synthesis of kalinin was further documented by indirect immunofluorescence on in vitro cultures of these cells. In non-Herlitz JEB patients, staining of BM was constantly detected. Impairment of expression of kalinin correlated with the lack of reactivity to the monoclonal antibody GB3, which detects the BM component nicein/BM600. These results clearly demonstrate a defect of kalinin expression in epithelial basement membranes of Herlitz JEB patients and suggest that kalinin may play a role in the pathogenesis of the disease. Further studies are in progress to define possible relationships between kalinin and nicein. 相似文献
999.
1000.
Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study 总被引:2,自引:0,他引:2
R. Canger A. C. Altamura O. Belvedere F. Monaco G. C. Monza G. C. Muscas R. Mutani B. Panetta F. Pisani G. Zaccara P. G. Zagnoni 《Acta neurologica Scandinavica》1990,82(1):9-13
The tolerability and pharmacokinetics of a new controlled-release (CR) formulation of carbamazepine (CBZ), were assessed in a multicentre, double-blind, cross-over trial, carried out in 48 epileptic patients (21 men, 27 women; mean age 34.2 years) on conventional CBZ monotherapy, but without complete seizure control (n = 22) or with intermittent side effects (n = 4), or with both (n = 22). Eligible patients were randomized to conventional CBZ or CR CBZ, each given in sequence at individualized daily doses, subdivided into the lowest number of administrations. Each period of the cross-over consisted of a first phase of optimal dose finding (lasting up to two months) and a second one of maintenance (lasting one month) used for evaluation. At the end of each period, a 10-h plasma CBZ and CBZ-epoxide concentration profile, as well as the tolerability and the efficacy of the drugs, were evaluated. The mean CBZ daily dose increased by 16% during the administration of the CR formulation. Fluctuations of total CBZ and 10, 11-epoxide plasma level daily profiles at steady-state were significantly (p less than 0.001) lower during CR CBZ treatment, leading to a significant (p less than 0.001) decrease in intermittent side effects (6 patients on CR CBZ vs 26 on conventional CBZ). Finally, 38 patients on CR CBZ (vs 15 patients on conventional CBZ) were treated with a b.i.d. regimen. 相似文献